TSX higher on employment data
BROOMFIELD, CO - Aclarion , Inc. (NASDAQ:ACON), a medical laboratory services provider, has reported a series of financing transactions that have significantly bolstered its cash position and ensured compliance with Nasdaq’s listing requirements. The company announced today that its current cash balance stands at approximately $15.2 million, positioning it well above the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2.5 million.
The positive financial development follows the approval by Aclarion’s stockholders on March 5, 2025, to issue common shares underlying the company’s Series A and Series B warrants, which were publicly offered on January 15, 2025. Post-approval, the Series B warrants were exercised using the alternative cashless exercise feature, leading to the issuance of around 12.7 million common shares. As a result, the total outstanding shares of Aclarion stand at approximately 13.7 million as of March 12, 2025. The company’s market capitalization currently stands at just $0.83 million, with the stock trading at $0.72, having declined 98.31% year-to-date.
Conversely, the Series A warrants have not been exercised, likely due to their adjusted exercise price of $6.70 per share, which is above the current market price. Unlike Series B warrants, Series A warrants do not have a cashless exercise option.
Additionally, Aclarion disclosed that during a special stockholders’ meeting on September 23, 2024, the board of directors was granted the authority to implement a reverse stock split within a range of one-for-five to one-for-fifty, at their discretion. This reverse stock split, if executed, could aid the company in maintaining compliance with the Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00.
The details of these corporate actions and financial updates are based on a press release statement from Aclarion, Inc. The company’s strategic financial maneuvers demonstrate its commitment to maintaining compliance with trading regulations and enhancing shareholder value. InvestingPro analysis reveals additional insights about Aclarion’s financial position, with 15+ more exclusive ProTips available to subscribers, covering everything from profitability metrics to growth prospects.
In other recent news, Aclarion, Inc. has announced several key developments. The company reported the approval of significant proposals by its shareholders, including the issuance of additional shares and an amendment to its charter, which allows an increase in authorized shares from 200 million to 300 million. This move reflects shareholder support for Aclarion’s strategic plans. Additionally, Aclarion has secured nearly $20 million in funding to fully support the CLARITY trial, a study aimed at validating the effectiveness of its Nociscan platform in improving surgical outcomes for chronic low back pain. The trial, led by Dr. Nicholas Theodore of Johns Hopkins, will enroll 300 patients to assess the platform’s ability to match surgical interventions to specific pain-causing discs.
Moreover, Aclarion has expanded its Nociscan sites in New York and New Jersey, in collaboration with RadNet (NASDAQ:RDNT), to meet the growing demand for its diagnostic tool. The expansion is part of a strategy to establish Nociscan as a standard of care for chronic low back pain. In another development, the company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that extends its rights in using magnetic resonance spectroscopy (MRS) for detecting biomarkers. This patent broadens the potential applications of Aclarion’s technology beyond discogenic low back pain. Additionally, Aclarion’s Nociscan platform was highlighted at the Selby Spine Conference, emphasizing its innovative approach to diagnosing discogenic pain using MR Spectroscopy and augmented intelligence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.